Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,543 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06648785Enrolling by invitationPhase 2
Modified chemo for GI cancers with non-curative intent
This trial tests a modified version of a common chemotherapy combination (capecitabine and oxaliplatin) for people with gastrointestinal cancers who are not expected to be cured. It aims to see if a simpler treatment schedule can be just as effective while reducing side effects.
Burlington, VermontAges 18 years+ - NCT06636435RecruitingPhase 1
Study of CBA-1205 for advanced cancers including liver, melanoma, and pediatric cancer
This trial tests a new drug called CBA-1205 for people with advanced solid tumors, liver cancer, melanoma, or certain childhood cancers that have not responded to standard treatments. The drug targets a protein called DLK1 found on some cancer cells.
Kashiwa, ChibaAges 2 years+ - NCT06636162RecruitingEarly Phase 1
Testing DSP-0390 before surgery for gliomas
This trial tests a drug called DSP-0390 in people with gliomas (a type of brain tumor). You take the drug for a short time before your scheduled surgery to see how it affects the tumor. It might help doctors find new ways to treat these tumors.
St Louis, MissouriAges 18 years+ - NCT06640010Recruiting
Studying why cancer treatments cause side effects
This study uses special cells grown in a lab to understand why some cancer treatments cause side effects. It may help researchers find ways to predict and prevent these side effects in the future.
Jacksonville, FloridaAges 18 years+ - NCT06621212RecruitingPhase 2
Combination therapy for relapsed or refractory AML
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
Hangzhou, ZhejiangAges 18 years+ - NCT06629584RecruitingPhase 2
Asciminib for second-line chronic phase CML
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
Houston, TexasAges 18 years+ - NCT06630416RecruitingPhase 2
Pemetrexed for advanced bladder and other cancers with certain gene changes
This trial tests if a chemotherapy drug called pemetrexed works better in advanced bladder cancer or other solid tumors that have specific genetic changes (MLL4, UTX, or MTAP). It is for people who have already tried at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT06624371RecruitingPhase 1
Atovaquone with radiation for children with brain tumors
This trial tests adding atovaquone to standard radiation therapy for children with aggressive brain tumors like high-grade glioma (a fast-growing brain cancer) or medulloblastoma. The goal is to see if this drug, which targets energy production in cancer cells, can make radiation work better.
Atlanta, GeorgiaAges 2–25 - NCT06630351Enrolling by invitation
Meaning-centered group therapy for caregiver wellbeing
This study tests whether group therapy focused on meaning and purpose can improve the wellbeing of people caring for someone with advanced cancer or another serious illness. Caregivers will join virtual group sessions and complete questionnaires about their feelings and stress.
Jacksonville, FloridaAges 18 years+ - NCT06618274Recruiting
Central navigation and online tool for new cancer patients
This study tests whether a central navigator—a person who helps guide you through cancer care—and an online tool can improve your experience. If you are a new cancer patient at UNC Medical Center, the study will see if this support helps you feel more informed and cared for.
Chapel Hill, North CarolinaAges 18 years+ - NCT06606990RecruitingPhase 1
Testing the drug CX-5461 for advanced solid tumors
This trial tests a new drug called CX-5461 (also known as pidnarulex) in people whose cancer has spread and hasn't been helped by standard treatments. It looks at how your body responds to the drug, which may target cancers with specific DNA repair problems.
Bethesda, MarylandAges 18 years+ - NCT06603987Enrolling by invitationPhase 1/Phase 2
Testing a new drug combination for recurrent solid tumors
This early-phase trial tests a new combination of drugs (CICS-1 and SPM-011) along with a special imaging scan to see if they can help people with hard-to-treat cancers that have come back. It may be an option if standard treatments are no longer working.
Osaka, OsakaAges 18–85 - NCT06600568Recruiting
New treatment for T-cell cancers
This trial is testing a new approach to treat T-cell cancers (leukemia and lymphoma). It may be an option for adults with these cancers who are otherwise in reasonably good health.
NaplesAges 18 years+ - NCT06616636RecruitingPhase 1
Rezatapopt and azacitidine for AML or MDS with a specific TP53 mutation
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
Tampa, FloridaAges 18 years+ - NCT06606366Recruiting
Genetic tumor testing using a blood test to guide treatment
This study uses a simple blood test to look at the genetic makeup of your tumor. The results may help your doctors choose the best treatment for you. You will need to provide a tumor sample or have a biopsy.
NiceAges 18 years+ - NCT06594445RecruitingPhase 1
GTB-3650 TriKE for high-risk MDS and relapsed AML
This trial tests a new immunotherapy called GTB-3650 TriKE for people with high-risk MDS or AML that has come back or not responded to treatment. It aims to boost your immune system to fight the cancer.
Minneapolis, MinnesotaAges 18 years+ - NCT06587100Recruiting
Wearable activity tracking to reduce hospital stays
This study tests if using a wearable activity tracker during radiation therapy can help reduce hospitalizations. It may help you stay healthier during treatment.
San Francisco, CaliforniaAges 18 years+ - NCT06587490RecruitingPhase 3
Radiation therapy for limited metastatic cancers
This trial tests whether adding focused, high-dose radiation (SABR) to standard drug therapy can better control cancer that has spread to a few spots in the body. It is for people starting or resuming cancer medicines for newly found or growing metastases.
La Jolla, CaliforniaAges 18 years+ - NCT06578650Recruiting
Restrata Mat for Skin Cancer Surgery Wounds
This study tests a special fiber mat called Restrata that is placed in the wound after skin cancer removal to help it heal. The mat acts as a scaffold for new skin growth and may help close the wound without needing a skin graft.
Las Vegas, NevadaAges 18 years+ - NCT06567691Enrolling by invitation
Comparing two ways to bypass cancer-caused stomach blockage
This trial compares two ways to bypass a stomach or intestinal blockage caused by cancer that cannot be cured with surgery. It tests a newer, less invasive procedure (endoscopic gastroenterostomy) against the standard surgical bypass (gastrojejunostomy) to see which works better for patients like you.
Nashville, TennesseeAges 18 years+ - NCT06579469Recruiting
Study of later effects of CAR T cell therapy
This study follows children and young adults who received CAR T cell therapy to understand any long-term side effects that may appear months to years later. By joining, you help researchers learn how to better care for patients after this treatment.
Aurora, ColoradoAges Up to 30 years - NCT06569316Recruiting
Genetic testing for cancer prevention in American Indian communities
This trial offers genetic testing to American Indian adults who have or have had cancer, to help prevent future cancers. It aims to make testing more accessible to these communities.
Scottsdale, ArizonaAges 18 years+ - NCT06580314RecruitingPhase 3
Olaparib with or without bevacizumab for ovarian cancer
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
Birmingham, AlabamaAges 18 years+ - NCT06574880RecruitingPhase 1/Phase 2
Radiation and Lutetium PSMA for locally advanced prostate cancer
This study tests a combination of focused radiation (SBRT) and a targeted radioactive drug (Lutetium PSMA) for men with prostate cancer that has spread to nearby lymph nodes or has high-risk features but has not yet reached distant organs. The goal is to see if this approach is safe and effective.
Cleveland, OhioAges 18 years+
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,543 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.